MacLean P. Nasrallah

3 ta ish

University of Pennsylvania

1. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

   Donald M. O’Rourke, MacLean P. Nasrallah, Arati Desai +18

   MaqolaOAOchiq kirish20174 iqtibos

   ABIABI:AkademIndex/2026.other.020482

2. Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial

   Stephen Bagley, Zev A. Binder, Lamia Lamrani +32

   MaqolaOAOchiq kirish20242 iqtibos

   ABIABI:AkademIndex/2026.other.102955

3. Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results

   Stephen Bagley, Meghan Logun, Joseph A. Fraietta +30

   MaqolaOAOchiq kirish20242 iqtibos

   ABIABI:AkademIndex/2026.other.102963